Breast cancer target treatment
In the fight against breast cancer, medical and technological advances have brought new hope to patients. Among them, target-oriented treatment is becoming an important component of breast cancer treatment as a precise treatment. Breast cancer is a malignant tumour that occurs in the mammography. It is one of the most common malignant tumours in women and poses a serious threat to their health and lives. The incidence of breast cancer is related to a number of factors, including genetic factors, hormone levels, lifestyle, etc. Common symptoms are breast swelling, breast pain, nipple spills, nipple changes, skin changes, etc. If these symptoms occur, they should be examined in a timely manner. The treatment of breast cancer includes surgery, treatment, chemotherapy, endocrinology treatment and target treatment. Different treatments apply to different patients, and doctors develop individualized treatments based on the patient ‘ s specific circumstances. Target therapy is a method of treating the specific molecular target of a tumor cell. Target-oriented treatment is more specific and selective than traditional chemotherapy, and can more accurately strike oncular cells while reducing damage to normal cells. In breast cancer, a number of specific molecular targets have been found, such as Her2 (human skin growth factor receptor 2) and VEGF (intravascular skin growth factor). The drugs for these targets can be used through different mechanisms, such as inhibiting the growth of tumour cells, promoting tumour cell decay and disrupting tumour vessels. Her2 Positive Breast Cancer and Target Treatment Her2 Positive Breast Cancer accounts for about 20-25% of all breast cancers. HeR2 is a trans-film protein receptor with low levels of expression in normal cells but overexpression in HeR2 positive breast cancer cells. Overexpression of Her2 causes the growth and multiplication of tumour cells to accelerate and to be less advanced. The main targets for HeR2 positive breast cancer treatments are tortoise resistance, Pattrust resistance, do-trastuzumab emtansine (T-DM1). (i) Twilight Twilight is the first target drug approved for HeR2 positive breast cancer. It is a human-sourced, monoclonic antibodies capable of combining uniquely with HeR2 receptors, blocking the transmission of HeR2 signals and thus inhibiting the growth and growth of tumour cells. The single anti-tratochorus, which is usually used in conjunction with chemotherapy, can significantly increase the survival of HeR2 positive breast cancer patients. The treatment is usually provided every three weeks by intravenous injection, lasting about one year. (ii) Pattojole mono-anti-Patojole is also a human-sourced monoclonic antibodies that are combined with different parts of the HeR2 receptor and that can be synergized with tutojo and enhance the treatment of HeR2 positive breast cancer. Pato-Chu is commonly used in combination with tuto-Choose resistance and chemotherapy, with a treatment programme of intravenous injections every three weeks. (iii) Doo-trastuzumab emtansine (T-DM1) T-DM1 is an anti-body pharmacist combination consisting of entangled mono- and cytotoxic emtansine. It is capable of transmitting cytotoxics to the HeR2 positive tumour cells, with greater tumour resistance. T-DM1 is usually used to treat progress in the treatment of HeR2-positive breast cancers following the treatment of tuttos mono-resistant and chemotherapy. The treatment programme is an intravenous injection every three weeks. iv. Other targets and drugs for breast cancer are important in the treatment of breast cancer, in addition to HER2. (i) VEGF VEGF is an angiogeneating factor that plays a key role in the growth and transfer of tumours. Targeted drugs for VEGF are mainly anti-Bayphor. A monoclonic antibodies of human origin can inhibit the activity of the VEGF, disrupt the tumour vessels and thus inhibit the growth of the tumor. The single antipolymers are usually used in combination with chemotherapy to treat late-stage breast cancer. (ii) PI3K/AKT/mTOR signal route PI3K/AKT/mTOR signal route plays an important role in cell growth, breeding, metabolism, etc. In the case of breast cancer, the abnormal activation of the signal route is related to the occurrence, development and resistance to tumours. Targeting drugs for PI3K/AKT/mTOR signal access are mainly Ivimos, etc. Ivimos is a mTOR inhibitor that can inhibit the tumour cell growth by inhibiting the movement of the signal. Ivimos is usually used in conjunction with endocrine treatment for hormonal receptor positives, and for late stage breast cancer of herpes. (i) High accuracy: Target-oriented treatment can treat a specific molecular target of a tumour cell, with greater specificity and selectivity, and can more accurately target tumour cells and reduce damage to normal cells. 2. The efficacy of treatment is significant: for specific types of breast cancer, such as Her2-positive breast cancer, targeted treatment can significantly improve the survival and quality of life of patients. 3. Good endurance: The side effects of the target-oriented treatment are relatively small and patient tolerance is better than traditional chemotherapy. 1. Limited scope of application: Targeting treatment does not apply to all breast cancer patients and only certain types of breast cancer can benefit from targeted treatment. 2. Drug resistance: tumour cells may produce resistance with extended treatment time, leading to a decrease in target-oriented treatment. 3. Higher costs: Targets tend to be more expensive to treat drugs, placing a greater financial burden on patients and families. (i) Pre-treatment assessment; At the same time, the doctor assesses the patient ‘ s state of health, including heart function, liver and kidney function, etc., to ensure that the patient is able to withstand targeted treatment. (ii) Monitoring during treatment. During target treatment, doctors closely monitor the patient ‘ s condition and adverse reactions. Patients should undergo periodic reviews, including blood tests, video-testing, etc., to assess the effectiveness of treatment and monitor adverse reactions. In the event of an adverse reaction, the doctor should be informed promptly so that the doctor can take appropriate action. (iii) Treatment of adverse effects. The adverse effects of target-oriented treatment are relatively low, but a number of adverse effects, such as cardiac toxicity, allergies, diarrhoea, etc., may also occur. In the case of different adverse effects, doctors take different treatments. For example, in the case of cardiac toxicity, the doctor conducts periodic cardiac function examinations and adjusts the treatment programme to the situation; in the case of allergies, the doctor treats allergies; in the case of diarrhoea, the doctor treats laxatives, etc. VII. The future outlook for breast cancer is also evolving as medical science and technology progress. In the future, we can expect more molecular targets to be found, more target drugs to be developed, and more treatment options for breast cancer patients. At the same time, with the development of precision medicine, we can more precisely identify the molecular target of the patient by means of genetic tests and develop more personalized treatment programmes for the patient. In addition, joint treatment is one of the future directions of breast cancer targeting, which can improve the effectiveness of treatment and overcome drug resistance by combining different targets with drugs or with other treatment methods. In short, the targeting of breast cancer is a precise and effective treatment that gives new hope to breast cancer patients. In the future, as medical science and technology continue to advance, we believe that the target of breast cancer will achieve more tangible results in terms of evangelizing more patients.
